Market research
INNT 9 Meters Biopharma, Inc
NASDAQ USD Not available
Latest close
As of 05 Dec 2024
Test a moving-average rule with historical data.
Market facts
- Market cap
- 23M
- P/E ratio
- Not available
- Analyst target
- 10
- Dividend yield
- 0.0%
- Beta
- -0.54
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Not available
- Industry
- Not available
- ISIN
- Not available
- Market cap
- 23M
- P/E ratio
- Not available
- Analyst target
- 10
- Dividend yield
- 0.0%
- Beta
- -0.54
About
About 9 Meters Biopharma, Inc
9 Meters Biopharma, Inc. operates as a rare, orphan, and unmet needs-focused GI company. The company is advancing its drug candidates for short bowel syndrome and celiac disease. Its product candidates include NM-002, a proprietary long-acting GLP-1 agonist into Phase 2 trial for short bowel syndrome; and larazotide, a Phase 3 tight junction regulator being evaluated for patient-reported symptom improvement in non-responsive celiac disease. The company's pipeline products also includes NM-004, an oral gut restricted immunomodulator and NM-003, a long-acting GLP-2 analogue, both of which are under orphan indication selection. 9 Meters Biopharma, Inc. owns global rights to its products. The company is based in Raleigh, North Carolina.
Research context
9 Meters Biopharma, Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the INNT discussion.
5 years, 7 months ago
9 Meters Biopharma, Inc is currently in a long term uptrend where the price is trading 20.2% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the sector with a price to sales ratio of 0.0.
Based on the above factors, 9 Meters Biopharma, Inc gets an overall score of 2/5.